We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 231

Clarification of the role of China National Medical Products Administration
  • CMS
  • China
  • October 9 2018

The State Council of the PRC released a document on 11 September 2018, clarifying the role of the recently restructured National Medical Products


Review of recent listings of biotechnology companies by way of Chapter 18A of the Hong Kong Main Board Listing Rules
  • King & Wood Mallesons
  • Hong Kong
  • September 28 2018

Since the new regime for listing of innovative companies was put in place four months ago, there has been a number of biotechnology companies seeking


China Accepts Overseas Clinical Trial Data to Expedite Drugs Registration in China
  • CMS
  • China
  • September 3 2018

On 6 July 2018, the China Food and Drug Administration ("CFDA") issued the Technical Guiding Principles for the Acceptance of the Overseas Clinical


CDE solicitation on the list of urgently needed drugs
  • CMS
  • China
  • September 3 2018

The Centre for Drug Evaluation ("CDE") of the CNDA released the List of Overseas Drugs in Urgent Need ("List") on 8 August 2018. The List was open for


Rules of accepting overseas clinical trial data
  • CMS
  • China
  • September 3 2018

CNDA issued the Guiding Technical Principles for the Acceptance of Overseas Clinical Trial Data of Drugs ("Principles") on 10 July 2018, which


Vaccine scandal in China
  • CMS
  • China
  • September 3 2018

The communist party's most powerful body, Politburo Standing Committee of the Communist Party of China, decided to sack 6 top officers after the


CNDA adjusts the proceeding of clinical trial application
  • CMS
  • China
  • September 3 2018

CNDA released the Announcement on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs ("Announcement") on 24 July 2018


从我不是药神看中国的仿制药存在的问题和解决的路径
  • Wanhuida Peksung
  • China
  • August 17 2018

一部意外走红的电影我不是药神让治癌神药“格列卫”家喻户晓同时也再次让仿制药成为了大众关注的焦点同样的药效为何来自印度的仿制药格列卫价格如此低廉


Life Sciences: Compliance and enforcement in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to compliance and dishonest practices in China


Life Sciences: product regulation and liability in China
  • Ropes & Gray LLP
  • China, Global
  • July 31 2018

A structured guide to product regulation and liability laws in China